Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV

We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Pediatric infectious disease journal 2018-06, Vol.37 (6), p.595-597
Hauptverfasser:	Brophy, Jason, Bitnun, Ari, Alimenti, Ariane, Lapointe, Normand, Samson, Lindy, Read, Stanley, Karatzios, Christos, Dobson, Simon, Moses, Erin, Blitz, Sandra, Lipsky, Nancy-Grace, Ogilvie, Gina, Walmsley, Sharon, Raboud, Janet, Money, Deborah
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antibodies, Viral - blood Canada CD4 Lymphocyte Count Child Female HIV Infections - virology Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - adverse effects Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - therapeutic use Humans Immunogenicity, Vaccine Longitudinal Studies Papillomavirus Infections - prevention & control Prospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We evaluated quadrivalent human papillomavirus vaccine seroresponses among 35 girls living with HIV (9–13 years of ages) and compared with data on girls without HIV, as part of a subgroup analysis. The quadrivalent human papillomavirus vaccine was safe and well tolerated. However, antibody response was significantly lower in girls living with HIV relative to girls without HIV. HIV virologic suppression predicted better antibody response.
ISSN:	0891-3668 1532-0987
DOI:	10.1097/INF.0000000000001874